|
The controversial abscopal effect: A single-center experience about the combination of stereotactic radiotherapy with pembrolizumab in patients with metastatic dMMR/MSI-H colorectal cancer. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; MSD |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; AstraZeneca |
Speakers' Bureau - Amgen; Merck; MSD; SERVIER |
Travel, Accommodations, Expenses - Bayer; Celgene; Ipsen; Pfizer; Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bayer; BMS; Celgene; Hutchmed; Menarini; Merck Serono; MSD Oncology; Roche; Sanofi; SERVIER |
Speakers' Bureau - amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; celgene; Lilly; Merck Serono; Roche; Sanofi; Takeda |
Travel, Accommodations, Expenses - Bayer; Roche |